Flexion Therapeutics Inc Revenue Growth Rates (FLXN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Flexion Therapeutics Inc   (NASDAQ: FLXN)
 

FLXN's Revenue Growth by Quarter and Year

Flexion Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FLXN Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September 21.33
2nd Quarter June 28.18
1st Quarter March 24.59
FY 74.10





FLXN Revenue third quarter 2021 Y/Y Growth Comment
Flexion Therapeutics Inc reported decrease in Revenue in the third quarter 2021 by -9.86% to $ 21.33 millions, from the same quarter in 2020.
The decrease in the third quarter 2021 Flexion Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 322.65%.

Looking into third quarter 2021 results within Major Pharmaceutical Preparations industry 175 other companies have achieved higher Revenue growth. While Flexion Therapeutics Inc ' s Revenue decline of -9.86% ranks overall at the positon no. 3246 in the third quarter 2021.


FLXN Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - 11.25 % 147.9 % 2550 %
3rd Quarter September -9.86 % 8.58 % 211.73 % -
2nd Quarter June 82.39 % -8.85 % 346.05 % -
1st Quarter March 22.16 % 90.62 % 382.19 % -
FY   - 17.27 % 223.93 % -

Financial Statements
Flexion Therapeutics Inc 's third quarter 2021 Revenue $ 21.33 millions FLXN's Income Statement
Flexion Therapeutics Inc 's third quarter 2020 Revenue $ 23.66 millions Quarterly FLXN's Income Statement


FLXN Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - 11.2 % 8.54 % 36.48 %
3rd Quarter September -24.32 % 53.14 % 28.55 % 83.95 %
2nd Quarter June 14.6 % -23.25 % 60.51 % 73.52 %
1st Quarter March -6.54 % -14.88 % 10.69 % 508.33 %
FY (Year on Year)   - 17.27 % 223.93 % -


Back to FLXN Growth rate Comparisons >> Back to FLXN Growth rate Comparisons >>


Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #176
Healthcare Sector #454
Overall #3246

Revenue Y/Y Growth Statistics
High Average Low
2588.17 % 322.65 % -9.88 %
(Dec 31 2018)   (Sep 30 2021)
Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #176
Healthcare Sector #454
Overall #3246
Revenue Y/Y Growth Statistics
High Average Low
2588.17 % 322.65 % -9.88 %
(Dec 31 2018)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Flexion Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
518.03 % 55.33 % -24.31 %
(Mar 31 2018)  


FLXN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2021 Flexion Therapeutics Inc disclosed fall in Revenue from the second quarter by -24.32% to $ 21.33 millions, from $ 28.18 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2021 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 178 other companies have achieved higher Revenue quarter on quarter growth. While Flexion Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3811.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #179
Healthcare Sector #586
Overall #3811
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #179
Healthcare Sector #586
Overall #3811
Revenue Q/Q Growth Statistics
High Average Low
518.03 % 55.33 % -24.31 %
(Mar 31 2018)  


FLXN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2021 Flexion Therapeutics Inc disclosed fall in Revenue from the second quarter by -24.32% to $ 21.33 millions, from $ 28.18 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2021 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 178 other companies have achieved higher Revenue quarter on quarter growth. While Flexion Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3811.


Flexion Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)
Cumulative Revenue 12 Months Ending $ 100.40 $ 102.74 $ 90.01 $ 85.55 $ 82.90
Y / Y Revenue Growth (TTM) 21.12 % 26.81 % 9.08 % 17.26 % 40.87 %
Year on Year Revenue Growth Overall Ranking # 727 # 498 # 1146 # 492 # 350
Seqeuential Revenue Change (TTM) -2.28 % 14.14 % 5.22 % 3.2 % 2.32 %
Seq. Revenue Growth (TTM) Overall Ranking # 2670 # 416 # 984 # 922 # 873


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Flexion Therapeutics Inc 's cumulative twelve months Revenue were $ 100 millions, company would post below average annual Revenue growth of 2.32% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Flexion Therapeutics Inc 's Revenue growth from the 28.18% growth in Jun 30 2021.

In the Healthcare sector 160 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 498 to 727.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 161
Overall # 727

Revenue TTM Y/Y Growth Statistics
High Average Low
341.26 %
 103.48 %
9.08 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 364
S&P 500 # 2670
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Flexion Therapeutics Inc 's cumulative twelve months Revenue were $ 100 millions, company would post below average annual Revenue growth of 9.08% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Flexion Therapeutics Inc 's Revenue growth from the 28.18% growth in Jun 30 2021.

In the Healthcare sector 160 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 498 to 727.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 161
Overall # 727

Revenue TTM Y/Y Growth Statistics
High Average Low
341.26 %
103.48 %
9.08 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 364
S&P 500 # 2670




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FLXN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2021
Enanta Pharmaceuticals Inc-0.24%$ -0.237 millions
Zimmer Biomet Holdings Inc -0.27%$ -0.275 millions
Community Health Systems Inc -0.35%$ -0.352 millions
Quest Diagnostics Inc-0.43%$ -0.431 millions
Koru Medical Systems Inc -0.65%$ -0.654 millions
Organon and Co -0.81%$ -0.806 millions
Avanos Medical Inc -0.86%$ -0.862 millions
Cytomx Therapeutics Inc -1.13%$ -1.130 millions
Bausch Health Companies Inc -1.26%$ -1.263 millions
Xtant Medical Holdings Inc -1.71%$ -1.705 millions
Ani Pharmaceuticals Inc-1.73%$ -1.733 millions
Mimedx Group Inc -1.91%$ -1.911 millions
Clovis Oncology inc -2.21%$ -2.208 millions
Teva Pharmaceutical Industries Limited-2.29%$ -2.288 millions
Elutia Inc -2.45%$ -2.455 millions
Alimera Sciences Inc-2.57%$ -2.566 millions
Nuwellis Inc -2.68%$ -2.679 millions
Pressure Biosciences Inc -2.90%$ -2.903 millions
Lifevantage Corp-2.92%$ -2.924 millions
Immunitybio inc -2.94%$ -2.941 millions
Luna Innovations Inc-3.43%$ -3.425 millions
Cardiovascular Systems Inc -3.59%$ -3.591 millions
Rayont Inc -3.69%$ -3.695 millions
Vyant Bio Inc -3.95%$ -3.954 millions
Hookipa Pharma inc -4.11%$ -4.109 millions
Supernus Pharmaceuticals inc -4.30%$ -4.300 millions
Procyon Corporation-4.51%$ -4.515 millions
Healthcare Services Group Inc -4.67%$ -4.670 millions
Old Ayala Inc -5.02%$ -5.015 millions
Societal Cdmo Inc -5.44%$ -5.444 millions


About Flexion Therapeutics Inc Revenue Growth Rates (FLXN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.